1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

作者：X. Le, L. Hendriks, Alessandro Morabito, L. Bonanno, Isamu Okamoto, J.W. Goldman, H.A. Yu, O.T. Brustugun, Tarje Onsøien Halvorsen, Yu Jung Kim, Kristen Ashley Marrone, B.C. Cho, Jonathan Wesley Riess, Adrianus Johannes De Langen, Zofia Piotrowska, Helen Ambrose, Peter J. Smith, John M. Lehman, P.G. Fraenkel, Sarah B. Goldberg · 发表于：Journal of Thoracic Oncology · 年份：2025 · DOI：10.1016/s1556-0864(25)00196-0 · 被引用次数：23 · 研究领域：Lung Cancer Treatments and Mutations、Sarcoma Diagnosis and Treatment、Colorectal Cancer Treatments and Studies